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KEY MESSAGE
The reproductive microbiome is implicated in female reproductive health and is probably also implicated in pregnancy 
outcomes. Understanding how to assess and diagnose microbiome dysbiosis in the female reproductive tract could lead to 
improvements in reproductive outcomes.
ABSTRACT
The interest in and understanding of the human microbiome has grown remarkably over recent years. Advances in molecular 
techniques have allowed researchers to identify and study the microbiota and also use this information to develop therapeutic 
solutions for a spectrum of conditions. Alongside the growing interest in the microbiome, societal changes have resulted in 
many couples looking to start families later in life, therefore increasing the demand for assisted reproductive technologies. 
Combining these trends, it makes sense that clinicians are eager to understand and exploit the microbiome of their patients, 
i.e. the reproductive microbiome, in order to help them achieve their goal of becoming parents. This paper aims to provide an 
overview of the current and future research into the reproductive microbiome in relation to fertility and also share clinical practice 
recommendations for physicians who are new to this field or unsure about how they can utilise what is known to help their patients.
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INTRODUCTION
S ince the first IVF baby was born in 1978, assisted reproductive technologies (ART) have become safer, more successful and more 
accessible; couples are choosing to have 
children later in life and the demand for 
ART is rapidly increasing (Faddy et al., 
2018). However, some women are unable 
to become pregnant, or experience a 
pregnancy loss or a preterm delivery. A 
new perspective on fertility is emerging 
as a result of increasing knowledge 
about the microbiome – and its role in 
reproductive health.
The first observation of non-pathogenic 
bacteria inhabiting the human body 
was of Escherichia coli in the intestine 
of healthy children in 1885. Since then, 
other commensal bacteria (bacteria that 
live in harmony with the host) inhabiting 
different parts of the human body, such 
as nasal and oral cavities, skin and the 
urogenital tract, have been discovered 
throughout the 20th century. Their role 
has been underestimated and in general, 
microbes were considered a threat 
to human health. Due to advances in 
sequencing technology, the literature 
has started to highlight the role of 
commensal bacteria (the microbiota) 
in normal physiology. In the mutualistic 
relationship between microbial 
communities and the human host, the 
host provides the nutrients to support 
bacterial growth, while the microbial 
communities provide defence against 
pathogens, shape the development 
and maturation of the immune system, 
help to digest food and fibre, produce 
vitamins and metabolize xenobiotics 
(Puebla-Barragan and Reid, 2019). Of 
note, the term microbiota refers to all of 
the micro-organisms in an environment, 
including bacteria, archaea and single-
cell eukaryotes (and sometimes viruses), 
and the term microbiome refers to the 
collection of genomes of the microbiota.
At present, there are five distinct 
microbiomes according to body site 
– the oral cavity, nasal cavity, skin, 
genitourinary tract and gastrointestinal 
tract (Kumar and Chordia, 2017). Within 
these distinct anatomical locations there 
are further microbial habitats, such as 
the tongue, cheek and lip of the oral 
cavity (Kumar and Chordia, 2017). 
Whereas the gut microbiota has by far 
the most dense and diverse microbial 
community, in the lower reproductive 
tract, a healthy microbiota is dominated 
by Lactobacillus species. Lactobacilli are 
bacteria that produce lactic acid and 
protect the vagina by sustaining a low pH 
that is prohibitive to the growth of most 
bacteria. The upper reproductive tract, 
long considered sterile, also has its own 
specific microbiota, which is 100 to 1000 
times less dense (Baker et al., 2018), 
but dominated by a greater variety of 
bacterial species and also different strains 
of Lactobacillus than the healthy vaginal 
microbiota (Moreno and Franasiak, 
2017).
The aim of this work is to briefly discuss 
the current research on the reproductive 
microbiome of female fertility patients 
in order to provide expert opinion on 
how to utilise this knowledge in clinical 
practice of infertility diagnosis and 
treatment. Bacterial therapies, commonly 
known as probiotics, are also increasingly 
researched, a natural consequence 
of our expanding knowledge of the 
microbiome. Targeted probiotics can 
replenish depleted microbiota, restore 
healthy conditions and consequently 
help treat infections and illness (Puebla-
Barragan and Reid, 2019).
MATERIALS AND METHODS
A panel of 37 fertility experts, including 
clinicians from across Europe, met to 
generate best practice recommendations 
for fertility experts interested in utilising 
the microbiome to improve their clinical 
practice. Small groups were formed for 
initial discussion of four key topics:
1 Clinical assessment: How is the 
reproductive microbial ecosystem 
being assessed in women? Which tools 
are being used and in which patients?
2 Endometrium and implantation: 
What is the role of the endometrial 
microbiome in endometrial 
receptivity, implantation and recurrent 
implantation failure?
3 Infertility: How should we evaluate and 
treat infertile patients and patients 
with bacterial vaginosis utilising the 
microbiome?
4 Birth: What techniques can be used 
to evaluate microbial structures and 
evaluate risk for preterm birth and 
pregnancy loss in pregnant women?
A full list of the discussion topics was 
compiled (see Supplementary Material). 
The entire group came together to 
discuss all topics and the agreed 
statements were used as a basis to 
produce a series of recommendations 
for clinical practice supported by the 
literature. These recommendations 
appear as section titles throughout the 
paper and have been organised into 
three sections. First, a brief overview of 
the current literature on the relationship 
between the reproductive microbiome 
and fertility (Part I); second, nine 
clinical practice recommendations for 
fertility experts (Part II); and third, seven 
statements about the future of research 
into the reproductive microbiome (Part 
III).
Part I: Current literature
There are strong indications that the 
vaginal and endometrial microbiomes 
are associated with female reproductive 
health.
The vaginal microbiota is of great interest 
due to its complexity, the increasing 
knowledge of its role in women's health 
and its influence on reproductivity 
(Moreno and Simon, 2019). As changes 
in vaginal microbiota homeostasis or 
disrupted microbiota, referred to as 
dysbiosis, can be the cause of infertility 
and preterm birth, there is increasing 
interest in the characteristics of a healthy 
microbiota and in different ways that this 
can be re-established (Bedaiwy, 2019; 
García-Velasco et al., 2017; Puca and 
Hoyne, 2017). Dysbiosis is also associated 
with endometriosis, although it is as 
yet unclear whether dysbiosis causes 
endometriosis, or endometriosis induces 
dysbiosis. As of November 2019, there 
are 94 clinical trials registered on https://
clinicaltrials.gov that include the search 
terms ‘pregnancy’ and ‘microbiome’. 
Seventeen of these are specifically linked 
to the vaginal/endometrial microbiome.
The vaginal microbiome plays an 
important role in protecting the vagina 
– the first barrier from the external 
environment to the upper reproductive 
tract. A better understanding of 
the vaginal microbiome is therefore 
mandatory to further our understanding 
of natural fertility and reproductive 
technology.
As per our current knowledge, in non-
pregnant, healthy women the vaginal 
microbiome is dominated by four 
Lactobacillus species: L. crispatus, L. 
iners, L. jensenii or L. gasseri (Ravel 
et al., 2011). The vaginal microbiota can 
be characterized by the presence or 
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absence of certain bacterial species. 
In 2011, Ravel et al. (2011) identified 
five vaginal microbial community state 
types (CST); four of them (I, II, III and 
V) are Lactobacillus-dominant and are 
more commonly found in European and 
Asian women. CST-IV, more frequent 
in Hispanic and African-American 
women, differs due to the increased 
abundance of strictly anaerobic bacteria 
(Gardnerella, Ureaplasma) and reduced 
presence of Lactobacillaceae (Ravel 
et al., 2011). Lactobacillus spp. produce 
lactic acid that helps to keep the vaginal 
pH below 4.5 and creates inhospitable 
conditions for pathogens to grow 
(Graver and Wade, 2011). The vaginal 
microbiota composition shows large 
ethnic differences and varies throughout 
the woman's lifetime depending on 
physiological events, like menstrual cycle 
and pregnancy, and external factors, like 
sexual activity, hygiene habits and medical 
treatments (Gajer et al., 2012; Ravel 
et al., 2011; Zhou et al., 2007).
The vaginal microbiota and its 
relation to infertility
Bacterial vaginosis is one example 
of an altered state of the vaginal 
microbiome, characterized by depletion 
of Lactobacillus and augmented diversity 
of anaerobic bacteria. Bacterial vaginosis 
affects 20–50% of reproductive-age 
women and it represents a risk factor for 
subfertility and infertility (Mastromarino 
et al., 2014a; Sirota et al., 2014). 
Increased presence of specific bacteria 
(Atopobium vaginae, Ureaplasma 
vaginae, U. parvum, U. urealyticum 
and Gardnerella), normally observed 
in asymptomatic bacterial vaginosis, 
together with higher abundance of 
Candida and reduced vaginal and 
cervical Lactobacillus, is often present 
in women with fertility problems 
(Koedooder et al., 2019a). Moreover, 
vaginal dysbiosis reduces the local 
defences against sexually transmitted 
pathogens (Wiesenfeld, 2003) and 
ascension of pathogens up the fallopian 
tubes can affect reproductive health 
(Mastromarino et al., 2014a).
The vaginal microbiota and its 
relation to IVF outcomes
The vaginal microbiota has lately become 
an important factor in IVF. The lack of 
consensus on its role comes from the 
lack of common criteria to cross-check 
data, small sample size, and the lack 
of data due to the novelty of the field. 
Altered vaginal microbiota and bacterial 
vaginosis may be related to poor 
pregnancy outcomes. Therefore, patients 
undergoing IVF should be screened 
and eventually treated to enhance the 
chances of success.
Several studies confirm that a vaginal 
microbiota rich in Lactobacillus spp. 
without bacterial vaginosis, either clinical 
or subclinical, leads to more positive 
outcomes with ART (Babu et al., 2017; 
Eckert et al., 2003; Mangot-Bertrand 
et al., 2013; Moore et al., 2000). Haahr 
et al. (2016a) studied the microbiota 
of 84 women undergoing IVF and 
found a strong relationship between 
microbiota composition and pregnancy. 
Of the 22 women who had an altered 
composition, only two women (9%) 
achieved a clinical pregnancy. Out of 
the 62 women with a normal microbiota 
composition, 29 women (47%) achieved 
a clinical pregnancy. Koedooder et al. 
(2019b) performed a prospective study of 
reproductive-age women undergoing IVF 
and found that embryo implantation was 
less successful in women with reduced 
Lactobacillus spp. in their vaginal 
microbiota. The authors proposed an 
algorithm, utilising the IS-pro sequencing 
method, to predict the IVF success 
rate based on the vaginal microbiota 
composition. They identified women with 
a low chance of becoming pregnant due 
to reduced Lactobacillus in the vaginal 
microbiota (18% of the dataset of 192 
women). The model was 94% accurate 
(with high specificity [97%], but low 
sensitivity [26%]): 32 out of 34 women 
with an unfavourable profile did not 
achieve pregnancy. An external validation 
cohort study further supported the 
prediction specificity. According to high 
versus low Lactobacillus dominance the 
women were divided into two subgroups 
with favourable and unfavourable 
prediction, respectively. None of the 
women in the unfavourable group 
became pregnant (Koedooder et al., 
2019b). In another study, Lactobacillus 
crispatus-dominant microbiomes were 
associated with higher live birth rate 
(Haahr et al., 2019; Vergaro et al., 2019). 
These findings suggest that a better 
knowledge about the vaginal microbiota 
prior to IVF may help both couples and 
healthcare professionals decide on the 
timing of their IVF cycles to maximize the 
results (Moreno and Simon, 2019).
At this point, however, it is very difficult 
to evaluate and to compare different 
studies because there are many variables 
to be considered, such as the time 
of collection of the vaginal samples, 
hormonal stimulation, fresh or frozen 
embryo transfer, oocyte donation, and 
success rate, defined as implantation 
or live birth (Fettweis et al., 2019). 
Moreover, novel and more standardized 
molecular approaches have improved the 
ability to detect micro-organisms and will 
enhance future results.
CST-IV is most commonly associated 
with negative ART outcomes
Women with bacterial vaginosis and 
aerobic vaginitis often present with a 
microbiota comparable to CST-IV (Smith 
and Ravel, 2017). Bacterial vaginosis 
or a perturbed microbiota are also a 
common factor in frequent preterm 
delivery or miscarriage (Buggio et al., 
2019; García-Velasco et al., 2017). 
CST-IV, with or without a diagnosed 
bacterial vaginosis, has been described 
as a common feature of preterm birth 
in Caucasian women (DiGiulio et al., 
2015; Donders et al., 2009) and African-
American women (Nelson et al., 2016). 
The vaginal microbiota is normally stable, 
Lactobacillus-dominated and less diverse 
during pregnancy (Aagaard et al., 2012). 
DiGiulio et al. (2015) observed that some 
women who presented with a CST-IV 
microbiota, depleted of Lactobacillus 
spp. throughout the gestational period, 
were more likely to deliver preterm. 
Another study found that a CST-IV 
vaginal microbiome was less frequent in 
women delivering at term even though it 
was not possible to define a correlation 
between this vaginal microbiota profile 
and preterm delivery (Romero et al., 
2014).
The endometrial microbiota and its 
relation to IVF
Previously it was believed that the upper 
reproductive tract was sterile. After the 
discovery of a specific and independent 
endometrial microbiome (Chen et al., 
2017), several studies concentrated on 
endometrial dysbiosis (Benner et al., 
2018; Moreno et al., 2016). Endometrial 
dysbiosis can be the cause of 
implantation failure and lead to infertility 
(Moreno and Simon, 2018).
Infertility treatment is intrinsically 
complicated; however, the delicacy and 
importance of the implantation phase 
has proven to be critical for positive 
outcomes (Diedrich et al., 2007). A 
Lactobacillus-dominant endometrium is 
more receptive than an endometrium 
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with high bacterial diversity and a low 
proportion of Lactobacilli. The results of 
a study by Moreno et al. (2016) highlight 
that women with a Lactobacillus-
dominant microbiota have a higher 
chance of success in implantation, 
60% versus 23% in non-Lactobacillus-
dominant microbiota; in pregnancy, 70% 
versus 33%; and in live birth, 60% versus 
7%. In this study Moreno et al. (2016) 
also found that women with a receptive 
endometrium (Lactobacillus-dominant) 
have a significantly lower miscarriage 
rate, 17% versus 60% as compared 
with women with a non-Lactobacillus-
dominant microbiota. These results 
differ from those obtained by Franasiak 
et al. (2016), who reported a comparable 
IVF success rate independent of 
the Lactobacillus dominance of the 
endometrial microbiota. Moreno et al. 
(2016) suggest this difference could be 
related to differences in the classification 
systems used in the two studies.
Hormonal fluctuations, especially 
in oestrogens, are implicated in the 
regulation of the vaginal microbiota and 
in the preparation of the endometrium 
for implantation and pregnancy (Wessels 
et al., 2018). It can be expected that 
hormones also influence the endometrial 
microbiota. Surprisingly, however, 
Moreno et al. (2016) found that the 
endometrial microbiota does not change 
under hormonal influence in the period 
preceding implantation. These results 
suggest that we should start to consider 
the endometrial microbiota and its 
health state prior to beginning IVF, in 
order to maximize the chance of positive 
outcomes.
The vaginal microbiota and its 
relation to preterm birth
The causes of preterm birth are very 
complex, making it challenging to prevent 
and also difficult to reduce the related 
infant mortality and the psychological 
and economic consequences of 
extended hospitalization of the newborn. 
As the vaginal microbiota is important 
for the health of the whole reproductive 
tract and for prevention of pathological 
infections, it can be expected that it 
affects not only pregnancy, but also 
delivery. The vaginal microbiome 
evolves during pregnancy in relation 
to gestational age and tends to lose 
the diversity observed in non-pregnant 
women (Freitas et al., 2017). Healthy 
pregnant women present a distinct 
vaginal microbiota profile dominated 
by Lactobacilli, with no differences 
depending on community type, ethnicity 
or body mass index (Aagaard et al., 
2012).
A non-Lactobacillus-dominant vaginal 
microbiota and increased bacterial 
diversity during pregnancy are associated 
with higher risk of preterm birth (Brown 
et al., 2019). A group of 96 women were 
divided into three groups according 
to high (38), low (22) or no risk (36) of 
preterm birth and followed from week 
6 of pregnancy. Augmented bacterial 
diversity and a concomitant reduced 
Lactobacillus spp. abundance were 
evident prior to premature rupture of 
membrane in 20% and 26% of high- and 
low-risk women, respectively. Only 3% of 
women that finished their pregnancy at 
term had an altered vaginal microbiota 
(Brown et al., 2019).
Black women are more likely to deliver 
preterm, yet the vaginal microbiota of 
pregnant women shows minor to no 
diversity across different ethnicities 
(Brown et al., 2019; Fettweis et al., 
2019). The National Institutes of Health's 
Integrative Human Microbiome Project 
includes samples of vaginal microbiome 
from more than 1500 pregnant women 
of diverse ancestries and omics data 
generated from a subset of about 600 
pregnancies. Fettweis et al. (2019) 
used these data to provide evidence 
of the role of Lactobacillus crispatus 
in lowering the risk of preterm birth. 
American women of European ancestry 
have a vaginal microbiota rich in L. 
crispatus and a significantly lower risk 
of preterm birth when compared with 
American women of African ancestry, 
who are more likely to have a vaginal 
microbiome poor in Lactobacillus spp. 
Additionally, bacterial vaginosis-associated 
bacterium 1, a bacterium that is positively 
associated with preterm birth, is more 
common in Black women (Fettweis 
et al., 2019). These results correspond 
to those obtained in British women with 
Caucasian, Asian and Black ethnicities. 
All Caucasian and Asian British women 
who delivered at term had a Lactobacilli-
dominant vaginal microbiome, but 12% of 
Black women who delivered at term were 
Lactobacilli-depleted (Brown et al., 2019; 
MacIntyre et al., 2015).
Some women with pre-pregnancy 
dysbiosis show a shift toward a healthy 
Lactobacillus-dominant bacterial 
community around weeks 15 to 20 of 
pregnancy. This normalization happens 
in about 50% of women (Hay et al., 
1994). However, there is also a strong 
association between pre-pregnancy 
bacterial vaginosis and preterm birth 
because ascending vaginal infections 
cause intrauterine inflammation, which is 
responsible for one-third of preterm birth 
(Buggio et al., 2019; Leitich et al., 2003).
To identify an increased risk of preterm 
birth early in pregnancy, despite 
the natural evolution of the vaginal 
microbiome during gestation, would 
lead to earlier diagnostics and possible 
therapeutic interventions. Based on 
thorough meta-analysis of vaginal 
microbiome datasets, a correlation 
between the vaginal microbiome in the 
first trimester and preterm delivery has 
been established. This correlation and 
related different microbiota profiles have 
been exploited to propose a ‘Taxonomic 
Composition Skew’ metric as a possible 
diagnostic tool to predict preterm 
delivery with high accuracy (Haque et al., 
2017).
Part II: Recommendations for clinical 
assessment and clinical practice1
For all infertility patients, ask if 
they have clinical symptoms (smell, 
discharge, urinary tract infection, 
Candida) currently and during their 
cycle
Our understanding of healthy and 
unhealthy vaginal microbiome is rapidly 
developing. When a woman is evaluated 
for vaginal dysbiosis, it is important to 
identify the cause in order to prescribe 
the proper treatment. Assessment of 
symptoms combined with microscopic 
and pH evaluation of the vaginal smear 
can help distinguish between bacterial 
vaginosis, trichomoniasis, candidiasis 
and lactobacillosis (Hainer and Gibson, 
2011). However, almost 30% of women 
with a vaginal disorder do not receive a 
proper diagnosis (Sha et al., 2005; van 
de Wijgert and Jespers, 2017).
Bacterial vaginosis is the most common 
vaginal disorder in reproductive-age 
women, although 50% of women are 
asymptomatic (Haahr et al., 2016a). 
Bacterial vaginosis is characterized by 
vaginal dysbiosis (altered microbiome 
composition) presenting as a depletion 
of Lactobacillus and a higher diversity 
of other anaerobic bacteria, such as 
Gardnerella, Mycoplasma and Prevotella 
(Turovskiy et al., 2011). Bacterial vaginosis 
 RBMO  VOLUME 00  ISSUE 0  2020 5
is positively associated with infertility, 
miscarriage and preterm birth (Donders 
et al., 2009). To confirm diagnosis 
and provide proper treatment, all 
women reporting vaginal symptoms 
(unusual discharge, burning or itching, 
unusual smell) should have their vaginal 
secretions tested (van de Wijgert and 
Jespers, 2017).
Urinary tract infections and yeast 
infections can be the cause of 
reproductive tract damage, i.e. tubal 
damage or pelvic inflammatory disease, 
and result in infertility (Mastromarino 
et al., 2014b). The main clinical 
symptoms of these conditions are 
malodourous vaginal discharge and 
itching/burning sensations (Klebanoff 
et al., 2004). Good clinical practice 
requires that women consulting for 
infertility treatment report whether 
they have suffered from one of these 
symptoms in the past, during their cycle, 
or at the moment of consultation.
For women with no symptoms there 
is currently no further testing 
recommended in clinical practice
Bacterial vaginosis is a deviation from 
a healthy Lactobacillus-dominant 
microbiota and several studies correlate 
infertility problems with vaginal dysbiosis 
(van de Wijgert et al., 2014; Weström, 
1994). Based on a cross-sectional study 
of 84 healthy women and 116 women 
with infertility problems, Babu et al. 
(2017) suggest adding a routine vaginal 
microbiota screening for all women 
undergoing infertility treatment. At 
present, however, this evidence is 
too limited to recommend a routine 
screening of all fertility patients. 
Moreover, molecular diagnostic 
testing is expensive and there is no 
supporting literature to recommend it 
in asymptomatic women (van der Veer 
et al., 2018).
If vaginal pH is below 4.5 this could 
indicate lactobacillosis
The pH of vaginal secretions is an 
important parameter for an accurate 
diagnosis in women presenting with 
vaginal symptoms such as burning or 
malodourous discharge. Many vaginal 
microbiota pathologies are characterized 
by Lactobacillus depletion, lower lactic 
acid production and a consequent 
increase in pH. However, lactobacillosis, a 
less common vaginal condition, presents 
with normal or lower pH values (Ventolini 
et al., 2014). Lactobacillosis presents 
comparable symptoms – itching/
burning, and abundant vaginal discharge 
– to those of bacterial vaginosis and is 
characterized by the higher abundance 
of long segmented Lactobacilli chains 
(Ventolini et al., 2014).
Vaginal dysbiosis can be measured 
in multiple ways, there are no gold 
standards in assessment. For women 
with symptoms/suspicions of dysbiosis, 
it is recommended to perform a 
speculum exam and pH test. If 
available also perform a wet smear, 
Gram Nugent score, and quantitative 
polymerase chain reaction (qPCR)
Several techniques have been developed 
to evaluate and confirm a diagnosis of 
bacterial vaginosis: the Amsel criteria, 
Nugent score and more recently qPCR. 
The Amsel criteria and Nugent score 
are inexpensive tests but they cannot 
adequately measure microbial complexity 
and thus may give inaccurate results 
(Mendling, 2016).
In 1983, Amsel et al. proposed four 
practical diagnostic criteria: (i) thin, 
white-greyish homogenous vaginal 
discharge; (ii) vaginal pH >4.5; (iii) a 
‘fishy’ odour after adding 10% potassium 
hydroxide to vaginal secretions; (iv) 
presence of epithelial cells coated with 
bacteria on wet mount microscopy. 
Bacterial vaginosis is confirmed if three 
out of four of these criteria are met. The 
Amsel criteria is an inexpensive technique 
that may provide the first evidence of 
dysbiosis. However, the evaluation of 
the results relies on microscopy, direct 
observation and experienced personnel 
(Kusters et al., 2015; Sha et al., 2005). 
Another limitation of the Amsel criteria 
is that the increased bacterial diversity 
causing dysbiosis is consistent with an 
altered pH, but might not alter the other 
Amsel criteria, thus resulting in a negative 
test. In different cohort studies, only 
about 40% of women with diagnosed 
bacterial vaginosis have been found 
positive according to the Amsel criteria 
(Sha et al., 2005; van der Wijgert et al., 
2014).
The Nugent scoring system, proposed in 
1991, is a Gram-stained scoring system 
of vaginal swabs. It is a 0–10 standardized 
scale evaluating vaginal microbiota based 
on the presence/absence of Lactobacilli 
spp., Gardnerella vaginalis and 
Mobiluncus spp. bacterial morphotypes. 
A lower abundance of Lactobacilli 
and an increased presence of other 
bacteria result in a higher Nugent score 
(Nugent et al., 1991). A Nugent score 
of 0–3 represents a healthy microbiota, 
4–6 an intermediate microbiota, and 
7–10 confirms bacterial vaginosis. The 
test is inexpensive and more sensitive 
than the Amsel criteria, but it takes a 
long time and requires an experienced 
microscopist to correctly evaluate results 
that remain subjective (van der Wijgert 
et al., 2014).
New molecular biology techniques based 
on DNA and RNA analysis, including 
qPCR, allow a more objective analysis. 
Even in the midst of great microbial 
complexity, the characterization of DNA/
RNA sequences allows the identification 
of bacteria present in minor amounts or 
which are difficult to cultivate (Cartwright 
et al., 2012). By utilising qPCR, a larger 
number of bacteria can be detected 
compared with bacteria culturing 
techniques (Kusters et al., 2015). The 
Amsel criteria and Nugent score can miss 
a diagnosis of bacterial vaginosis because 
they can underestimate the complexity 
of microbiota alterations (Cartwright 
et al., 2012). Recently, the performance 
of a novel diagnostic tool, the AmpliSens 
assay, was compared with the classical 
methods, and proposed for use in clinical 
practice as a more rapid, objective and 
accurate diagnosis (van den Munckhof 
et al., 2019).
There is limited evidence on whether 
uterocervical colonization should be 
routinely assessed
The discovery of a distinct uterine 
microbiota is recent and there is 
little consensus on the composition 
of a core healthy uterine microbiota 
(Baker et al., 2018). Nevertheless, 
authors agree on the hypothesis that 
uterine microbiota, independent of the 
vaginal microbiota, might play a role in 
infertility (Moreno and Franasiak, 2017). 
Further research is needed to better 
understand the composition and the 
role of uterine colonization, keeping in 
mind that low-density microbiota are 
extremely sensitive to microbial and 
DNA contamination. To date there is no 
evidence supporting clinical testing to 
evaluate the uterine microbiome (Baker 
et al., 2018).
Antibiotics should not be used on 
a routine basis to change vaginal 
typology
Antibiotics are not free from secondary 
effects, varying from skin rash to 
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anaphylaxis, and overuse can increase 
the chance of developing antibiotic 
resistance. The efficacy of using 
antibiotics in conjunction with IVF 
treatment is controversial (Haahr 
et al., 2016b; Kaye et al., 2017; Kroon 
et al., 2011; Moore et al., 2000). Use of 
antibiotics before embryo transfer could 
impact the normal healthy colonization 
of the endometrium and reduce the 
efficacy of the procedure (Kroon et al., 
2011). On the other hand, the risk of 
contamination of the upper reproductive 
tract by vaginal bacteria is higher during 
transcervical and transvaginal procedures 
and antibiotic prophylaxis could be 
preventive (García-Velasco et al., 
2017). Based on a systematic review, 
the American Society for Reproductive 
Medicine (2017) strongly recommends 
against the use of antibiotics before 
embryo transfer. There is an ongoing 
randomized clinical trial of IVF patients 
at Washington University to evaluate the 
clinical pregnancy rate when withholding 
routine prophylactic antibiotic therapy 
during IVF (NCT03386227).
The use of antibiotics can however 
be of relevance for certain repeated 
implantation failure (RIF) patients
Chronic endometritis is an inflammatory 
state of the uterine endometrium that is 
normally asymptomatic. The inflammatory 
state is the result of an imbalance 
between the microbiome and the host 
immune system, possibly due to micro-
organisms, viruses or parasites, but the 
aetiology remains unclear (Park et al., 
2016; Wu et al., 2017). The role of chronic 
endometritis in fertility has long been 
underestimated, but it is now recognized 
as a possible cause of not only infertility 
but also early miscarriage (Johnston-
MacAnanny et al., 2010). Chronic 
endometritis leads to a non-receptive 
endometrium which is a major cause of 
RIF (Margalioth et al., 2006). The fact that 
the upper reproductive tract is not sterile 
(Mitchell et al., 2015), and the latest data 
showing that both placenta and amniotic 
fluid may present bacteria of their own, 
have generated a new awareness to the 
role of the microbiota in pregnancy 
and newborn health (Schoenmakers 
et al., 2018). The efficacy of antibiotic 
therapy in treating women with certified 
chronic endometritis and RIF has been 
established. Women with no infection as 
compared with women with persistent 
infection after antibiotic therapy had 
higher rates of implantation, 37% versus 
17% (P = 0.069); clinical pregnancy, 65% 
versus 33% (P =  0.039); and live birth, 
61% versus 13% (P = 0.02) (Cicinelli et al., 
2015). Although data do not exist for their 
use presently, probiotics as a method of 
treating chronic endometritis represents a 
promising approach and requires further 
study.
Pre-conception counselling is useful 
and lifestyle habits can impact 
reproductive outcomes (possibly by 
modulation of the vaginal microbiota), 
therefore weight loss, physical activity 
and lifestyle changes should be 
discussed and encouraged in infertile 
patients
A woman's health is fundamental to a 
healthy pregnancy and for the future 
health of the baby (Stephenson et al., 
2018). Women who wish to conceive 
are likely to change bad habits, however 
advice is often inaccurate or incomplete 
(Bookari et al., 2017). Pre-conception diet 
and lifestyle changes can not only lead 
to better general health but also increase 
the chances of a positive reproductive 
outcome.
Obesity represents a major health 
threat with many related pathologies, 
including metabolic syndrome, diabetes, 
cardiovascular disease and cancer. The 
estimated reduction in fertility is 18% for 
obese women (Pantasri and Norman, 
2014). Weight loss is strongly related to 
improved ovulation, hormonal rebalance 
and increased pregnancy rate in obese 
women (Clark et al., 1995; Sim et al., 
2014). Diet and mild-to-moderate daily 
physical activity should be the first step in 
infertility treatments.
Smoking is another major health threat 
for society as a whole and in particular 
for infertile women. The pregnancy 
rate of heavy smokers (>10 cigarettes) 
is significantly lower when compared 
with that of non-heavy smokers (<10 
cigarettes) (34.1% versus 52.2%, 
respectively), and overall women who 
smoke are more likely to be subfertile 
(Bolumar et al., 1996). However, for 
women who smoke, pregnancy outcomes 
can be quickly changed as women 
who quit smoking have a time to first 
pregnancy that is comparable to that of 
non-smokers (Bolumar et al., 1996).
Diet and smoking are directly involved in 
bacterial vaginosis, and bacterial vaginosis 
is associated with infertility, pregnancy 
loss and preterm birth. Overweight 
and obese women are more likely than 
healthy-weight women to have a higher 
Nugent score and bacterial vaginosis 
(Brookheart et al., 2019). Women who 
smoke are more likely than non-smokers 
to have a CST-IV vaginal microbiota 
depleted in Lactobacillus spp., and a 
high Nugent score indicating a risk for 
bacterial vaginosis (Brotman et al., 2014).
Lifestyle changes, especially those 
that affect nutrition, can lead to 
changes in the gastrointestinal 
microbiome and could have a positive 
impact in infertile patients
Diet has a major impact on the gut 
microbiome, by far the densest and most 
metabolically active human-associated 
microbial community (Lozupone et al., 
2012; Vieira-Silva et al., 2016; Wu et al., 
2016), and so nutritional interventions 
may improve reproductive outcome 
partly through modulating the gut 
microbiome composition. A disturbed 
gut microbiota has been implicated in 
many diseases – inflammation, metabolic 
disorders, obesity and cancer (Cani 
et al., 2007; Hildebrandt et al., 2009; Le 
Chatelier et al., 2013; Ridlon et al., 2014) 
– most of which can also affect fertility. 
Therefore, the importance of microbial 
communities at body sites other than the 
reproductive tract have to be considered 
as potential actors in human fertility.
Part III: Future studies and research 
techniques to consider
Tobacco, alcohol, cannabis, stress, 
physical activity, infections, lack of 
sleep, body mass index, antibiotic 
exposure, drug exposure, sexual 
activity, diabetes/metabolic disorders 
and hygiene habits might impact 
microbiome composition; modification 
of these factors should be assessed 
in every study in order to assess their 
impact on the microbiota
The recent discovery of the non-sterility 
of the upper reproductive tract (Mitchell 
et al., 2015) and recent debate over 
whether even the placenta and amniotic 
fluid may present bacteria of their own, 
have brought a new awareness to the 
role of the microbiota in pregnancy and 
newborn health (Schoenmakers et al., 
2018). Moreover, a disturbed vaginal 
microbiota has proven to be a major 
factor in infertility, miscarriage and 
preterm birth (Moreno and Simon, 2019).
The human microbiota evolves naturally; 
the vaginal microbiota changes during 
pregnancy (MacIntyre et al., 2015) 
 RBMO  VOLUME 00  ISSUE 0  2020 7
and the gut microbiota evolves from 
childhood to old age (Woodmansey, 
2007) and can be altered due to 
exogenous pressures including poor 
nutrition, smoking, stress, drug exposure 
and antibiotic exposure (Gohir et al., 
2015; Falony et al., 2016; Wen and Duffy, 
2017). Consequently, lifestyle adjustment 
and maybe dietary supplements could be 
proposed to help women with infertility 
problems, to promote both pregnancy 
outcomes and newborn health. Future 
research should concentrate on 
the role of these external factors to 
further understand their impact on the 
microbiota.
The use of probiotics to treat atypical 
vaginal microbiota is being studied
In recent years many probiotic oral 
supplements have appeared on the 
market, with increased evidence of their 
efficacy, mostly to treat gastrointestinal 
conditions (Ford et al., 2014). Several 
oral and vaginal probiotics have been 
developed to help women restore healthy 
vaginal microbiota.
Back in 1992, a pioneering study 
reported that a daily oral dose of yogurt 
enriched with Lactobacillus acidophilus 
was effective in treating recurrent 
vulvovaginal candidal infections after 
6 months of treatment (Hilton et al., 
1992). Since then, many studies have 
investigated the role of Lactobacillus 
spp. supplementation in restoring 
the vaginal microbiota (Falagas 
et al., 2007). Products are mostly 
formulated with various combinations 
of Lactobacillaceae, including L. 
crispatus, L. gasseri, L. plantarum, L. 
reuteri and L. rhamnosus. The presence 
of Lactobacillus spp. is a recognized 
characteristic of a healthy vaginal 
microbiota (García-Velasco et al., 2017), 
while a decrease in their abundance 
is often associated with altered pH 
and dysbiosis, bacterial vaginosis 
or vulnerability to pathogens (Ravel 
et al., 2011). Several studies confirm 
the beneficial role of oral or vaginal 
probiotic supplementation in achieving 
and maintaining a healthy microbiota 
(Anukam et al., 2006; Homayouni 
et al., 2014; Reid et al., 2001, 2003). 
Others question probiotic efficacy, albeit 
confirming the absence of any adverse 
effect related to their use (Barrons and 
Tassone, 2008; Buggio et al., 2019).
There is consensus on the efficacy of 
vaginal probiotics when used in addition 
to antibiotic therapy. Lactobacillus 
spp. supplementation has proven 
effective in the prevention of recurrent 
infections after standard metronidazole 
therapy (Menard, 2011). Antibiotics 
are not species-specific, so while they 
fight pathogens, they also decrease 
Lactobacilli and other commensal 
bacteria, thus resulting in a depletion of 
healthy bacteria in the vaginal microbiota 
(Macklaim et al., 2015). The concomitant 
use of antibiotics and probiotics might be 
the optimal therapy to fight pathogens 
and correctly repopulate the vaginal 
microbiota (Moreno and Simon, 2019).
As previously discussed, bacterial 
vaginosis and unbalanced microbiota 
can reduce success in fertility treatment. 
Research on the efficacy of supplements 
in restoring vaginal health is quite new 
and has evolved quickly over the past 
few years as a result of next-generation 
techniques (Campisciano et al., 2017). 
There is yet to be consensus on the 
efficacy of probiotics (Anukam et al., 
2006; Barrons and Tassone, 2008; 
Buggio et al., 2019; Homayouni et al., 
2014; Reid et al., 2001, 2003), and 
conflicting results may be due to 
probiotic strain choice, or the posology 
adopted to treat specific conditions. 
To date, available data on probiotics 
to support infertility treatments are 
insufficient but promising (García-
Velasco et al., 2017). A future challenge 
is to confirm probiotic activity and 
to precisely characterize the specific 
strains with the aim of creating therapies 
effective in infertile women.
The use of probiotics to prevent 
preterm birth is supported by a large 
body of evidence (Kirihara et al., 
2018; Vitali et al., 2012). Kirihara et al. 
(2018) reported that a combination 
of probiotics (Streptococcus faecalis, 
Clostridium butyricum and Bacillus 
mesentericus) successfully improved 
perinatal outcome. A total of 121 women 
with high risk of preterm delivery were 
divided into two groups, one of which 
received the probiotics. The women 
receiving probiotics (n = 45) had longer 
gestations: only one woman (2%) 
delivered before 32 weeks, while in the 
control group 19 women (25%) delivered 
before 32 weeks. Overall, gestation was 
36 weeks on average in the probiotic 
group and 34 weeks on average in the 
control group. This work shows the 
beneficial effects of probiotics despite 
the intrinsic limits of retrospective 
studies and potential confounding 
factors. In another study, women 
receiving an oral, eight-strain probiotic 
containing a mixture of Lactobacillus, 
Streptococcus and Bifidobacterium 
strains in the last 3 months of pregnancy 
had modulated vaginal microbiota 
and an increase in anti-inflammatory 
cytokines (Vitali et al., 2012). Given that 
inflammation is a major cause of preterm 
birth (Romero et al., 2014), it is possible 
that reducing vaginal inflammation could 
have implications in preventing preterm 
birth.
Microbiota profiling should be used 
in a standardized manner (collection, 
analysis, statistics)
The boundaries of the healthy 
reproductive tract microbiota must be 
clearly defined before the relationship 
with fertility can be established. To 
date we have some important insights, 
but data are insufficient to definitively 
characterize healthy versus dysbiotic 
status. The first step towards this aim 
is to standardize protocols, sampling 
methods and sizes, sequencing 
techniques and bioinformatic pipelines 
(Koedooder et al., 2019a). This will 
provide comparable data and possibly 
lead to general conclusions that can be 
used as a basis for effective therapies 
(Koedooder et al., 2019a; Watson and 
Reid, 2018).
Prospective studies (randomized, 
controlled, with large patient 
numbers) need to be standardized in 
collection, laboratory techniques and 
statistical analyses in order to study 
the microbiota and its relation to 
fertility outcomes
A healthy reproductive tract microbiota 
is correlated to fertility and to positive 
fertility treatment outcomes. The 
research is rapidly growing, but 
many issues remain unexplored or 
controversial. Systematic reviews show 
that studies are difficult to compare 
because of varying cohort demographics, 
inclusion criteria, sample size, laboratory 
techniques, etc. (Fettweis et al., 2019; 
Peelen et al., 2019). Peelen et al. (2019) 
propose a database of essential and 
desirable items relating to quality, 
method and topic to overcome the low 
quality of information relating the vaginal 
microbiota. Improved study design 
and sampling strategies are needed to 
standardize research and establish causal 
relationships between microbiota and 
adverse outcomes.
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For research purposes one might 
consider assessing the microbiome 
in all fertility patients to gain more 
insight into pathophysiology and 
outcomes
Distinguishing a commensal microbiota 
from a pathophysiologic microbiota 
without altering standard clinical 
practice is an important step to better 
understand the reproductive microbiota. 
Franasiak et al. (2016) characterized the 
endometrial microbiota without altering 
standard clinical practice. At time of 
embryo transfer, the 5 mm distal part of 
the catheter was sterilely placed in a PCR 
tube and analysed by next-generation 
sequencing (NGS). The results of this 
study were not statistically significant, 
but they suggest a direction for future 
studies and propose a way to analyse 
the microbiota with very limited starting 
material and without changes to standard 
clinical practice. These techniques could 
be applied to all fertility patients and 
provide insight into pathophysiology.
NGS and other genetic testing 
methods are useful in research. More 
evidence is required to support routine 
use in diagnosing infertility, preterm 
birth and recurrent pregnancy loss
As the microbiota plays a role in 
infertility, recurrent pregnancy loss and 
preterm birth it is logical to consider it 
as a counterpart in infertility treatment. 
The questions are multiple. How do 
we define a healthy microbiome? 
Which analyses should we use? How 
do we correctly interpret the results? 
NGS has increased the resolution and 
accelerated the research, allowing full 
complex microbiota communities to be 
monitored. Recent studies show that 
small changes in vaginal microbiota 
can greatly affect fertility, therefore we 
need more specific tests in order to 
create accurate therapeutic protocols 
for infertility treatments (Campisciano 
et al., 2017). NGS has detected a new 
bacterium, Atopobium vagina, highly 
represented in the vaginal microbiota 
of women suffering from idiopathic 
infertility. With a less specific analysis, 
the Nugent score, no difference was 
detected between fertile and infertile 
women (Campisciano et al., 2017). This 
result demonstrates that we have only 
touched the surface and we must fully 
exploit new technologies to deepen the 
knowledge. Moreover, as we continue to 
move from research to clinical practice, 
this analysis is required in order to 
improve ART success rates (Haahr et al., 
2019; Koedooder et al., 2019a; Moreno 
et al., 2016).
Other genetic testing methods such as 
qPCR, phylogenetic microarrays (e.g. 
V-Chip) (Paily and Agans, 2011) and 
molecular fingerprinting (e.g. IS-pro™) 
(Koedooder et al., 2019b), have proved 
useful in microbiome profiling. There is 
an inherent trade-off to these techniques, 
forcing a choice between the broadness 
of the profiling or the resolution and 
sensitivity of the profiling. Metagenomic 
sequencing offers broad profiling, 
with very high definition in the case 
of shotgun metagenomic sequencing, 
however low-abundance species will be 
missed. IS-pro™ is, similarly, a broad-
spectrum molecular technique that 
depicts the relative composition of the 
dominant fraction of the microbiota. As 
discussed in Part 1, an algorithm using 
the IS-pro™ technique was successfully 
used for IVF failure prediction 
(Koedooder et al., 2019b). Phylogenetic 
microarrays contain probes that target 
specific species. It therefore offers fast 
results and high resolution but for a 
predetermined panel of micro-organisms 
of interest. qPCR is the technique most 
appropriate for low biomass specimens 
or to detect low-abundance species in a 
community (Haahr et al., 2019). qPCR 
assays are cumbersome if the panel of 
interest is extensive, but allow assessment 
of quantitatively specific elements of 
the microbiota at any level of resolution 
(from strain to full bacterial content) 
and will even detect bacteria that are 
present in very small amounts and that 
are difficult to cultivate (Cartwright 
et al., 2012), which could be important 
for the early detection of microbiota 
perturbations.
Perhaps in the future, NGS and other 
molecular techniques could be used 
prognostically for counselling to 
optimize the time of embryo transfer
Embryo transfer is a crucial step 
in fertility treatments and can fail 
for many reasons including uterine 
anatomy, immunological factors or 
embryo genetics. The reproductive 
tract microbiota is one variable that 
has recently been associated with 
embryo transfer failure. Several 
studies concentrate on the vaginal and 
endometrial microbiota to confirm 
their role in embryo transfer, and to 
better characterize the bacteria involved 
(Cicinelli et al., 2015; Koedooder et al., 
2019b). The introduction of NGS 
and molecular techniques allows the 
characterization of previously non-
culturable bacteria in altered microbiota 
(Lamont et al., 2011). These findings 
can boost our knowledge about 
the microbiota and provide a new 
perspective on which bacterial strains 
are involved in embryo transfer failure. 
Some preliminary studies show that 
molecular tests have a high sensitivity in 
detecting bacterial vaginosis: ATRiDA® 
(sensitivity 96.9%, specificity 70.2%) and 
AmpliSens® (sensitivity 80.6%, specificity 
>90%) (van den Munckhof et al., 2019; 
van der Veer et al., 2018). On the basis 
of new findings, future researchers 
should aim to incorporate diagnostic 
tools into clinical practice with the goal of 
optimizing the time of embryo transfer to 
maximize the success rate.
DISCUSSION
A more complete understanding of the 
role of the reproductive microbiome 
promises improvements to fertility 
treatments and a more nuanced 
understanding of reproductive health 
as a whole. The microbiome is the new 
frontier; the currently accumulated 
knowledge will propel the discovery of 
new treatment solutions and protocols 
for superior fertility outcomes. Although 
the field is new, there are already ways to 
utilise what is known to improve clinical 
practice and achieve better reproductive 
outcomes. Current and future research 
in large clinical cohorts should uncover 
more ways in which the microbiota 
can be modulated pre-conception and 
during pregnancy in order to minimize 
pregnancy loss and preterm birth and 
maximize implantation, pregnancy rate 
and at-term delivery of healthy babies.
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